The level of plasma trigliceride, total cholesterol and HDL cholesterol in different stages of human immunodeficiency virus (HIV) infection;Stȩzenia triglicerydów, cholesterolu całkowitego i cholesterolu HDL w róznych stadiach zakażenia ludzkim wirusem upośledzenia odporności (HIV)

Polskie Archiwum Medycyny Wewnetrznej

Volumn 101, Issue 2, 1999, Pages 145-150

  Rogowska Szadkowska, Dorota ^a   Borzuchowska, Agnieszka ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NONE

Author keywords

HIV infection; Lipid abnormalities

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; TRIGLYCERIDES;

EID: 0043206760     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nahlen B. L, Chu S.Y., Nwayamu O.C., Berkelman R.L, Martinez S.A., Rullan J.V: HIV wasting syndrome in the United States. AIDS, 1993, 7, 183.
2. Zangerle R., Reibnegger G., Wachter H., Fuchs D.: Weight loss in HIV-1 infection is associated with immune activation. AIDS, 1993, 7, 175.
3. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36 (Suppl. 2S), 3.
4. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41, 1.
5. Gonzalez-Clemente J.M., Miro J., Navarro M.P., Zamora L., Vilardell E.: High trigliceride levels as predictor of mortality in AIDS patients. AIDS, 1993, 7, 1022.
6. Grunfeld C., Hamadeh R., Tierney A., Wang J., Pierson R.N.: Hipertr.gliceridemia in the acquired immunodeficiency syndrome. N. Engl. J. Med., 1989, 86: 27.
7. Sauerwein H P.: AIDS versus acute septic states: similarities and dissimilarities.[W]: Organ metabolism and nutrition: idees for future critical care. Red.: Kinney J. M., Tucker H. N., Raven Press LTD, New York, 1994, 381-391.
8. Grunfeld C., Feingold K.R.: Metabolic disturbances and wasting m the acquired immunodeficiency syndrome. N. Engl. J. Med., 1992, 327, 329.
9. Grunfeld C., Pang M., Doerler W.,. Shigenaga J.K., Jensen P., Feingold K.R.: Lipids, lipoproteins, trigliceride clearance, and cytokines in human immunodeficiency syndrome. J. Clin. Endocrinol. Metab., 1992, 74, 1045.
10. Mildvan D., Machado S.G., Wites I., Grossberg S.E.: Endogenous Interferon and trigliceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet, 1992, 339, 453.
11. Clerici M., Shearer G.: A TH1 to TH2 switch is a critical step in the etiology of HIV infection. Immunol., Today 1993, 14, 107.
12. Andus T., Palitsch K.-D., Gross V, Schölmerich J.: Metabolische und endocrine Funktionen der Zytokine. Dtsch. Med. Wochenschr., 1993, 118, 306.
13. Aukurst P., Liabakk N.B., Muller R., Lien E., Espevik T., Froland S.S.: Serurn levels of tumor necrosis factor a (TNF-a) and soluble TNF receptors in human immunodeficiency type 1 infection - correlation to clinical, immunologic and virologic parameters. J. Infect. Dis., 1994, 169, 420.
14. Ladhervita J., Maury C.P.J., Teppo A.M., Repo H.: Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am. J. Med., 1988, 85, 289.
15. Matsuyama T., Kobayashi N., Yamamoto N.: Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS, 1991, 5, 1405.
16. Molina J.M., Schindler R., Ferriani R. i wsp.: Production of cytokines by peripheral blood monocytes/macrophages infected with human immunodeficiensy virus type l (HIV-1). J. Infect. Dis., 1990, 161, 888.
17. Food and Drug Administration: Public health advisory on protease inhibitors for HIV treatment. JAMA,1997, 278, 379.
18. Hengel R.L, Watts N.B., Lennox J.L: Benign symmetric lipomatosis associated with protease inhibitors. Lancet, 1997, 350, 1596.
19. Miller K.D., Jones E., Yanowski J.A., Shankar R., Feuerstein I., Falloon J.: Visceral abdominal-fat accumulation associated with use of indinavir. Lancet, 1998, 351, 871.
20. Lipsky J.J.: Abnormal fat accumulation in patients with HIV-1 infection. Lancet, 1998, 351, 847.
21. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M.: "Buffalo hump" in men with HIV-1 infection. Lancet, 1998, 351, 867.
22. Carr A., Samaras C., Chisholm D.J., Cooper D.A.: Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet, 1998, 35, 1881.
23. American College of Phisicians: Guidelines for using serum cholesterol, high-density lipoprotein cholesterol and trigliceride levels as screening tests for preventing coronary heart disease in adults. Ann. Intern. Med., 1996, 124, 515.